Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 4 1Phase 1 1

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 1371Other hematologic neoplasm 418Myeloid 34Plasma cell 29Sarcoma 27Dermatologic 15CNS 12Classical hematology 9Tumor-Agnostic 4Thoracic 4Breast 4Head & Neck 3Genitourinary 3Other solid neoplasm 2Gynecologic 2Gastrointestinal 2Other neoplasm 1Other 1

Conditions

Neoplasms 4

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Blood Specimen Collection 28Radiosurgery 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Rituximab × Tumor-Agnostic × Clear all
NCT06031233 2026-03-30

MINUTE

Isala

Phase 4 Recruiting
776 enrolled
Tumor-Agnostic

Neoplasms

NCT05615974 2024-12-19

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

LaNova Medicines Limited

Phase 1/2 Recruiting
139 enrolled
Tumor-Agnostic

Neoplasms

NCT03783403 2024-09-19

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

Celgene

Phase 1 Terminated
206 enrolled
Tumor-Agnostic

Neoplasms

NCT00983619 2020-05-13

A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies

MedImmune LLC

Phase 1/2 Completed
136 enrolled 56 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡